Company intelligence / Profile preview

MondoGEN

Stans, Nidwalden, Switzerland

Ownership: Private
Development stage: Other

Overview

MondoGEN refers to two historical biotechnology entities: mondoGEN AG, a Swiss biotech company, and MondoGen GmbH, a German gene therapy company. The Swiss mondoGEN AG was a subsidiary of mondoBIOTECH AG focused on repurposing drugs for orphan diseases, most notably developing aviptadil (a synthetic vasoactive intestinal peptide) for pulmonary arterial hypertension (PAH) and sarcoidosis before being combined into mondoBIOTECH holding AG (later Relief Therapeutics). The German MondoGen GmbH was a 1998 spin-off from the Max Planck Society located in Martinsried that developed gene therapies for liver diseases until its acquisition by HepaVec AG in 1998/1999.

Therapeutic areas: GastroenterologyPulmonologyCardiovascularImmunology
Modalities: PeptidesBiologicGene therapy
Industry: Biotech

Partnerships

Biogen

Beyond the preview

Go deeper on MondoGEN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MondoGEN.

Explore the full profile